Montreal, Quebec — May 6, 2026 — Leads & Copy — Knight Therapeutics Inc. (TSX:GUD) announced the voting results from its Annual General Meeting of Shareholders, held virtually in Montreal, Quebec.
Shareholders elected each director nominee listed in the Management Information Circular dated April 3, 2026.
Jonathan Ross Goodman was elected with 67,561,253 votes for (95.00%) and 3,556,866 votes against (5.00%). James C. Gale was elected with 70,354,667 votes for (98.93%) and 763,452 votes against (1.07%). Samira Sakhia was elected with 70,961,675 votes for (99.78%) and 156,444 votes against (0.22%). Robert N. Lande was elected with 70,849,287 votes for (99.62%) and 268,832 votes against (0.38%). Michael J. Tremblay was elected with 69,898,922 votes for (98.29%) and 1,219,197 votes against (1.71%). Nicolás Sujoy was elected with 70,851,887 votes for (99.63%) and 266,232 votes against (0.37%). Janice Murray was elected with 70,855,752 votes for (99.63%) and 262,367 votes against (0.37%).
Ernst & Young LLP were appointed as external auditors for the next year. Shareholders, present in person or represented by proxy, cast a majority vote in favor of the appointment, and the directors were authorized to determine their remuneration. The vote was 72,019,754 for (99.85%) and 107,533 votes withheld (0.15%).
The results of the final votes regarding all matters subject to a vote during the Meeting will be available on SEDAR (www.sedarplus.ca).
Knight Therapeutics Inc., headquartered in Montreal, Canada, focuses on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM.
Source: Knight Therapeutics Inc.
